In a nutshell This trial will investigate the effects of bb2121 in patients with non-responsive multiple myeloma (MM) who have progressed after standard treatment. The percentage of patients who respond and the percentage of patients who respond completely will be the main measures in this study. This study will take place in the United States and...
Read MorePerformance status-1 – Slightly symptomatic Posts on Medivizor
Looking for patients with B-cell non-Hodgkin’s lymphoma to test a new treatment option
In a nutshell This trial is examining the safety and effectiveness of mosunetuzumab plus polatuzumab vedotin for B-cell non-Hodgkin’s lymphoma (NHL). The main outcomes to be measured will be the complete response rate and the occurrence of side effects after treatment. This study is recruiting in Miami, Florida, New York City, New York, and Duarte,...
Read MoreSearching for patients to test a new treatment for unresponsive multiple myeloma.
In a nutshell This trial is comparing the effectiveness of a new therapy, bb2121, to commonly used combinations of drugs for relapsing/refractory (unresponsive) multiple myeloma (RRMM). The main outcome to be measured is the time from the start of treatment until cancer worsens. The details Many patients are cured with standard treatments, such as...
Read MoreLooking for patients with advanced colorectal cancer to a test two different treatment combinations
In a nutshell This phase 3 trial is examining the effectiveness of arfolitixorin versus leucovorin (folinic acid) when added to a combined treatment with 5-fluorouracil, oxaliplatin, and bevacizumab (FOB) to treat advanced colorectal cancer. The main outcome to be measured is the cancer response to the treatment. The details Treatment with...
Read MoreLooking for patients with metastatic colorectal cancer to test a combined treatment
In a nutshell This phase 3 trial is examining the effectiveness of a combination treatment with panitumumab (Vectibix), leucovorin and fluorouracil after chemotherapy combined with panitumumab in metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured is progression-free survival (PFS; time from treatment to...
Read MoreLooking for patients with non-small cell lung cancer that has spread to test a treatment combination
In a nutshell This trial is looking to compare the effectiveness of local therapy (surgery or radiotherapy) plus ipilimumab (Yervoy) and nivolumab (Opdivo) to ipilimumab and nivolumab alone in patients with metastatic (has spread) non-small cell lung cancer (NSCLC). The main outcome that will be measured is overall...
Read MoreLooking for patients with relapsed/refractory Hodgkin lymphoma to test treatment with ibrutinib
In a nutshell This study is investigating the effectiveness of ibrutinib (Imbruvica) for patients with relapsed or refractory (not responding to treatment) classical Hodgkin’s lymphoma (HL). Effectiveness is measured by the overall response rate (percentage of patients whose cancer shrinks or completely disappears after treatment). This study is...
Read MoreLooking for patients with triple negative inoperable breast cancer to test a new treatment option atezolizumab
In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) when used with chemotherapy in patients with inoperable, recurrent triple-negative breast cancer. The main outcome to be measured will be the overall survival (time from treatment until death from any cause) of participants. The...
Read MoreWhich is the better treatment for breast cancer to improve quality of life?
In a nutshell This study aimed to find out if the quality of life after treatment was different in women who had whole breast irradiation (radiation treatment to the whole breast) for early breast cancer compared to women who had accelerated partial breast irradiation (short radiation treatment to part of the breast) with brachytherapy. The...
Read MoreDo patients with advanced lung cancer change their exercise habits?
In a nutshell This study examined the exercise behavior and physical fitness in patients with advanced lung cancer. The authors concluded that regular exercise and therefore physical fitness is reduced after diagnosis of advanced lung cancer. Some background Cancer patients frequently have reduced physical ability and quality of life due to fatigue...
Read MoreIs targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?
In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...
Read MoreThe socioeconomic impact of cachexia in elderly patients with advanced lung cancer
In a nutshell This study looked at the impact of cachexia (weakness or wasting of the body) in elderly patients with advanced non-small-cell lung cancer on disability, hospitalization and medical costs. The authors concluded that patients with cachexia had a higher risk of disability, longer hospital stays and higher medical costs, while being treated...
Read More
